Predictive factors associated with involved margins in breast cancer treated with neoadjuvant chemotherapy followed by breast-conserving therapy.


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 10 04 2019
revised: 03 05 2019
accepted: 09 06 2019
pubmed: 18 6 2019
medline: 6 2 2020
entrez: 18 6 2019
Statut: ppublish

Résumé

This study sought to identify predictive factors of involved surgical margins in breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC) to help guide the surgical procedure. Retrospective study of patients who had BCS after NAC between January 2008 and December 2013. tumor-involved margin, defined by tumor cells on ink for invasive cancer and tumor-free margin < 2 mm for DCIS. Ninety-seven patients were included. The median age of patients was 46 years old [28-71]. The initial average tumor size was 47.8 mm [+/- 18.6]. Twelve patients (12.4%) had involved tumor margins on final histology after BCS and NAC. According to the multivariate model including only preoperative variables of positive margins, initial ultrasound tumor size ≤ 27 mm (p = 0.045) and low SBR grade (p = 0.009) were independently associated with tumor-involved margins. According to the multivariate model including pre- and postoperative variables of positive margins, ductal carcinomain situ was also independently associated with tumor-involved margins (p = 0.021). Initial ultrasound tumor size ≤ 27 mm and low SBR grade were independently associated with tumor-involved margins. These preoperative data were very helpful to guide the surgical procedure in breast cancer.

Identifiants

pubmed: 31207391
pii: S2468-7847(19)30211-9
doi: 10.1016/j.jogoh.2019.06.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

467-472

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Elise Davoine (E)

Rennes University Hospital, Gynecology Department, Hôpital Sud, 16 bd de Bulgarie, 35000 Rennes, France; University of Rennes 1, Faculty of Medicine, 2 rue Henri Le Guilloux, 35000 Rennes, France.

Ludivine Dion (L)

Rennes University Hospital, Gynecology Department, Hôpital Sud, 16 bd de Bulgarie, 35000 Rennes, France; University of Rennes 1, Faculty of Medicine, 2 rue Henri Le Guilloux, 35000 Rennes, France.

Krystel Nyangoh Timoh (K)

Rennes University Hospital, Gynecology Department, Hôpital Sud, 16 bd de Bulgarie, 35000 Rennes, France; University of Rennes 1, Faculty of Medicine, 2 rue Henri Le Guilloux, 35000 Rennes, France.

Eugenie Beraud (E)

Rennes University Hospital, Radiology Department, Hôpital Sud, 16 bd de Bulgarie, 35000 Rennes, France.

Patrick Tas (P)

Eugène Marquis Comprehensive Cancer Center, Pathology Department, Avenue Bataille Flandres Dunkerque, 35000 Rennes, France; Rennes University Hospital, Pathology Department, 2 rue Henri Le Guilloux, 35000 Rennes, France.

Aude Tavenard (A)

Rennes University Hospital, Clinical Research Department, Pontchaillou, 2 rue Henri Le Guilloux, 35000 Rennes, France.

Bruno Laviolle (B)

Rennes University Hospital, Clinical Research Department, Pontchaillou, 2 rue Henri Le Guilloux, 35000 Rennes, France.

Christophe Perrin (C)

Eugène Marquis Comprehensive Cancer Center, Medical Oncology Department, Avenue Bataille Flandres Dunkerque, 35000 Rennes, France.

Fabrice Foucher (F)

Rennes University Hospital, Gynecology Department, Hôpital Sud, 16 bd de Bulgarie, 35000 Rennes, France.

Jean Levêque (J)

Rennes University Hospital, Gynecology Department, Hôpital Sud, 16 bd de Bulgarie, 35000 Rennes, France; University of Rennes 1, Faculty of Medicine, 2 rue Henri Le Guilloux, 35000 Rennes, France; INSERM, ER440-OSS, CRLCC Eugène Marquis, Rennes, France.

Vincent Lavoué (V)

Rennes University Hospital, Gynecology Department, Hôpital Sud, 16 bd de Bulgarie, 35000 Rennes, France; University of Rennes 1, Faculty of Medicine, 2 rue Henri Le Guilloux, 35000 Rennes, France; INSERM, ER440-OSS, CRLCC Eugène Marquis, Rennes, France. Electronic address: vincent.lavoue@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH